Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device
Abbott Tests New Balloon-Expandable TAVI System for Aortic Stenosis, Launches First Patient Procedures With Investigational TAVI Device
Abbott (NYSE:ABT) today announced the first patient procedures with its investigational transcatheter aortic valve implantation (TAVI) balloon-expandable system for treating symptomatic severe aortic stenosis. This investigational Abbott TAVI system is the first step toward Abbott's software-guided balloon-expandable TAVI system and is designed to build a foundation for artificial intelligence (AI) guided procedures. Once the investigational balloon-expandable system completes clinical development and is approved by regulatory authorities, Abbott's structural heart portfolio will offer physicians another TAVI management option to meet the patient's needs along with the company's Navitor TAVI system, which is already commercially available.
Abbott(纽交所:ABT)今天宣布,其用于治疗症状性严重主动脉瓣狭窄的研究性经皮主动脉瓣植入(TAVI)可膨胀球囊系统已进行了首例患者手术。这一研究性Abbott TAVI系统是通往Abbott软件引导的可膨胀球囊TAVI系统的第一步,旨在构建人工智能(AI)引导程序的基础。一旦研究性可膨胀球囊系统完成临床开发并获得监管部门批准,Abbott的结构性心脏产品组合将为医生提供另一种TAVI管理选择,以满足患者需求,同时公司已经商业化的Navitor TAVI系统。
The aortic valve is a heart valve that controls the flow of oxygen-rich blood to the body. With age, calcium may build up in the valve and cause it to narrow – a condition known as aortic stenosis – resulting in the heart needing to work harder to pump blood through the valve. Left untreated, aortic stenosis can cause symptoms, such as chest pain, shortness of breath and fainting, and it can weaken the heart and become life-threatening. Patients who are at risk of open-heart surgery due to age, frailty or having multiple other conditions may benefit from minimally invasive treatment options where a device is delivered to the heart through an artery in the leg. Aortic stenosis remains the most common primary valve disease and its prevalence increases with age, ranging from approximately 2% in adults 70-80 years of age to 9% in adults older than 80 years.1
主动脉瓣是控制富含氧血液流向身体的心脏瓣膜。随着年龄增长,瓣膜中可能会积聚钙质并导致其变窄 - 这种情况称为主动脉瓣狭窄 - 导致心脏需要更加努力地通过瓣膜泵送血液。如果不加治疗,主动脉瓣狭窄可能引起症状,如胸痛、呼吸急促和晕厥,并可能导致心脏衰弱并危及生命。由于年龄、体弱或存在多种其他疾病的风险,无法接受开放性心脏手术的患者可能从经皮治疗选项中受益,其中通过腿动脉将设备输送到心脏。主动脉瓣狭窄仍然是最常见的原发性瓣膜疾病,其患病率随年龄增长而增加,成人70-80岁的患病率约为2%,80岁以上成人的患病率为9%。
The investigational system is a type of balloon-expandable TAVI device, which works by crimping the new heart valve on a deflated balloon. The balloon with the mounted valve is then inserted into the body through an artery in the groin and routed up to the heart. Once properly positioned inside the narrowed heart valve, the balloon is inflated to expand the new valve, taking over the function of the patient's narrow native heart valve. The balloon is then deflated and removed from the body.
这一研究性系统是一种可膨胀球囊TAVI设备,通过在一个放气的气囊上压缩新的心脏瓣膜来发挥作用。带有安装瓣膜的气囊然后通过大腿的动脉插入体内,并向上引导至心脏。一旦正确定位在狭窄的心脏瓣膜内部,气囊被充气以扩展新的瓣膜,取代患者狭窄原生心脏瓣膜的功能。然后放气并将气囊取出体外。